Work

GLP-1 Receptor Agonist Use for Uncontrolled Type 2 Diabetes and Insufficient Weight Loss after Bariatric Surgery

Year: 2024
Type: article
Study design: Case Report
Abstract: A 52-year-old male with type 2 diabetes mellitus returns for follow up.His past medical history includes: obesity, dyslipidemia, hypertension, and prior sleeve gastrectomy six years ago.Before his sleeve gastrectomy, his diabetes was managed with insulin glargine & lixisenatide injection 60 units daily, empagliflozin 10 mg daily, and metformin 1000 mg twice daily.His BMI was 35.8, weighing 221 pounds, with height of 5 foot 7 inches.Labs were significant for a hemoglobin A1c of 8.7%.He lost 50 pounds three years after his bariatric surgery, with a nadir of 171 pounds.Insulin glargine was reduced to 14 units daily.At this point, he began gaining weight and his blood sugars increased.Empagliflozin was started for its weight loss benefit and was discontinued due to overnight polyuria.He switched to dulaglutide 0.75 mg weekly, which was better tolerated.Dulaglutide was titrated to 1.5 mg weekly, and insulin was stopped.Hemoglobin A1c improved to 6.6%.Dulaglutide was further increased to 3 mg weekly for additional glucose control and weight loss.He continues to tolerate dulaglutide without any side effects or hypoglycemia.His weight was now 165 pounds, and his A1c of 6.2% (see Table 1).
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7047235220
FWCI:
Cites: 11
Cited by:
Related to: 10